Bristol-Myers Squibb
BMS looks to leverage real-world data, with Flatiron collab
May 3, 2018Medical Communications, Sales and Marketing Bristol-Myers Squibb, Flatiron health, biotech, drugs, pharma, pharmaceutical
Bristol-Myers Squibb has extended its existing collaboration with Flatiron Health by three years and expanded the efforts both will be …
BMS pulls the plug on Phase 3 trials of IDO1 inhibitor
May 2, 2018Research and Development BMS, Bristol-Myers Squibb, IDO1, opdivo, pharma, phase 3
Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor acquired through its $800 million acquisition …
Novartis snatches Amgen and BMS veteran for CMO and Drug Development Head
April 19, 2018Medical Communications Amgen, BMS, Bristol-Myers Squibb, Novartis, appointment, pharma
Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, …
BMS restructure will transfer 90 jobs from NY state to Massachusetts and New Jersey
March 15, 2018Manufacturing and Production BMS, Bristol-Myers Squibb, Massachusetts, New York, new jersey, pharma
Bristol-Myers Squibb has announced plans to relocate around 90 roles from the state of New York to facilities in Massachusetts …
BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression
February 6, 2018Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma
Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …
Bristol-Myers Squibb’s Yervoy scores EU approval in paediatric melanoma
January 23, 2018Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, EU, Yervoy, pharma
Bristol-Myers Squibb has revealed that its immunotherapy Yervoy (ipilimumab) has received an expanded indication from the European Commission, approving the …
BMS partners again with the company behind Opdivo
December 14, 2017Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, opdivo, pharma, pharmaceutical
Bristol-Myers Squibb has once again struck a deal with Ono Pharmaceutical for multiple programs, seeking to discover a boost to …
BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer
October 13, 2017Sales and Marketing BMS, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, NICE, opdivo, pharma, pharmaceutical
Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for …
BMS’ Opdivo to finally be made available to lung cancer patients in the UK
September 20, 2017Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, biotech, drugs, opdivo, pharma, pharmaceutical
It is two and a half years since patients with lung cancer in the US were able to receive Bristol-Myers …
BMS’ Opdivo gets a potential first-line boost in kidney cancer
September 8, 2017Medical Communications, Research and Development Bristol-Myers Squibb, biotech, drugs, opdivo, pharma, pharmaceutical
Bristol-Myers Squibb has announced results from a Phase 3 trial showing that patients treated with Opdivo alongside Yervoy in patients …
BMS hit by clinical trial hold from FDA
September 7, 2017Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, immunotherapy, opdivo, pharma, pharmaceutical
The FDA has placed a partial hold on clinical trials involving Bristol-Myers Squibb’s immunotherapy treatment, Opdivo, when used in combination …
MSD plays catch up with €464m deal for fledgling biotech
September 7, 2017Sales and Marketing Bristol-Myers Squibb, MSD, biotech, drugs, keytruda, pharma, pharmaceutical
MSD has announced that it will acquire Rigontec, a three-year old German biotech, in a deal worth an initial €115 …
Bristol-Myers Squibb’s $2.3 billion gamble to boost cancer pipeline
August 4, 2017Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, IFM Therapeutics, biotech, drugs, pharma, pharmaceutical
Bristol-Myers Squibb has agreed a deal to acquire IFM Therapeutics for a potential $2.3 billion. The latter is a biotech …
SMC reverses decision on Opdivo for kidney cancer
June 12, 2017Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, SMC, opdivo
The Scottish Medicines Consortium (SMC) has performed a U-turn on its decision regarding Opdivo (nivolumab), and will now allow patients …
BMS’ Opdivo scores eighth approval in Europe for bladder cancer
June 5, 2017Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, Europe, European Commission, bladder cancer, immunotherapy
Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the …
Latest content
